If you have been tracking Beam Therapeutics (BEAM), you may have noticed a renewed wave of investor curiosity following recent reports from BMO Capital. The spotlight is on the company’s BEAM-302 DNA ...

ZEEKR is being taken private by Geely at a modest premium, limiting future upside and shareholder influence in the deal. Find ...